

Bod continues to achieve upward trajectory in medicinal cannabis prescriptions

- **516 prescriptions of Bod’s MediCabilis™ product filled in April 2020 – 35% growth on March 2020 and third largest volume month on record**
- **Repeat prescriptions accounted for 60% of April volumes outlining patient satisfaction – repeat purchases continue to increase month on month**
- **3,459 MediCabilis™ prescriptions filled in FY2020 – significantly adds to revenue profile**
- **Ongoing upward trajectory in prescription numbers anticipated and driven by:**
 - **Participation in Europe’s largest cannabis registry Project Twenty21**
 - **Product uptake from patients in the United Kingdom**
 - **Sales of recently launched 2.5% and 10% CBD isolate products which increase the addressable market by 46%**

Sydney, Australia – 20 May 2020: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) is pleased to advise that it is continuing to experience significant uptake of its MediCabilis™ product amongst Australian patients.

During April 2020, Bod filled 516 prescriptions, marking a 35% increase on March 2020 (March prescriptions: 382) and the Company’s third largest volume month on record. The large volumes generated in April leave Bod well positioned to exceed Q3 MediCabilis™ prescriptions, which totalled 1,099.

Bod has now filled a total of 3,459 prescriptions in FY2020, which has added significantly to the Company’s growing revenue profile. This upward trajectory in prescription volumes clearly demonstrates MediCabilis™ traction in the Australian market with a wide range of new and repeat patients utilising the product.

Repeat prescriptions for April accounted for 60% of the month’s total volume. Pleasingly, the amount of repeat prescriptions achieved each month is increasing and the Company is confident this will continue as volumes grow.




Image one: cumulative units sold on a month-by-month basis

While MediCabilis™ is prescribed for a range of conditions, the top four indications that patients are using the product for is chronic pain, seizure management, neuropathic pain and anxiety.

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 91.4m
 Market Capitalisation ~\$28.3m

BOARD & MANAGEMENT

Mr Mark Masterson
 Non-Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Akash Bedi
 Non-Executive Director

Mr George Livery
 Non-Executive Director

Mr Patrice Malard
 Non-Executive Director

Mr Simon O’Loughlin
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Continued growth in prescription volumes across the remainder of FY2020 and beyond is anticipated following Bod's entry into the United Kingdom (refer ASX announcement: 4 May 2020) and participation in Europe's largest medicinal cannabis registry, Project Twenty21 (refer ASX announcement: 11 May 2020).

Further, the Company expects that recently launched CBD isolates in varying strengths (refer ASX announcement: 11 February 2020) will further underpin volumes, as each product allows Bod to pursue an additional 46% of the prescription market in Australia.

CEO Jo Patterson said: "Achieving 516 MediCabilis™ prescriptions and a strong repeat purchase rate in April is a great result for Bod and we are pleased with the steady increase in sales.

"Following our recent market entry into the United Kingdom and through our participation in Project Twenty21, we anticipate that prescription volumes will continue to rise.

"The increase in volumes and the Company's recent expansion into the UK leave Bod well positioned to potentially deliver its largest volume quarter of medicinal cannabis sales ever.

"We continue to enjoy strong demand for our MediCabilis™ product range amongst patients in Australia and the United Kingdom and I look forward to updating shareholders on ongoing product uptake across the coming months.

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538